Yoshihiro Maruo1, Keisuke Nagasaki2, Katsuyuki Matsui2, Yu Mimura2, Asami Mori2, Maki Fukami2, Yoshihiro Takeuchi2. 1. Department of PediatricsShiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192, JapanDepartment of PediatricsNiigata University, Niigata, JapanDepartment of Molecular EndocrinologyNational Research Institute for Child Health and Development, Tokyo, Japan maruo@belle.shiga-med.ac.jp. 2. Department of PediatricsShiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192, JapanDepartment of PediatricsNiigata University, Niigata, JapanDepartment of Molecular EndocrinologyNational Research Institute for Child Health and Development, Tokyo, Japan.
Abstract
AIM: We previously reported that biallelic mutations in dual oxidase 2 (DUOX2) cause transient hypothyroidism. Since then, many cases with DUOX2 mutations have been reported. However, the clinical features and prognosis of individuals with DUOX2 defects have not been clarified. OBJECTIVE: We investigated the prognosis of patients with congenital hypothyroidism (CH) due to DUOX2 mutations. PATIENTS: Twenty-five patients were identified by a neonatal screening program and included seven familial cases. Their serum TSH values ranged from 18.9 to 734.6 mU/l. Twenty-two of the patients had low serum free thyroxine (fT4) levels (0.17-1.1 ng/dl). Twenty-four of the patients were treated with L-thyroxine. METHODS: We analyzed the DUOX2, thyroid peroxidase, Na(+)/I(-) symporter, and dual oxidase maturation factor 2 genes of these 25 patients by PCR-amplified direct sequencing. An additional 11 genes were analyzed in 11 of the 25 patients using next-generation sequencing. RESULTS: All patients had biallelic DUOX2 mutations, and seven novel alleles were detected. Fourteen of the patients were able to discontinue replacement therapy, and seven were receiving reduced L-thyroxine doses. Normalization of thyroglobulin lagged several years behind the completion of treatment. Two patients showed permanent hypothyroidism. Except for one case of a learning disability, growth and psychomotor development were normal. CONCLUSION: The prognosis of Japanese patients with DUOX2 defects was usually transient CH. Delayed improvement of thyroglobulin indicates that these patients have subclinical hypothyroidism. Hypothyroidism did not recur in patients during the study period (up to 18 years old).
AIM: We previously reported that biallelic mutations in dual oxidase 2 (DUOX2) cause transient hypothyroidism. Since then, many cases with DUOX2 mutations have been reported. However, the clinical features and prognosis of individuals with DUOX2 defects have not been clarified. OBJECTIVE: We investigated the prognosis of patients with congenital hypothyroidism (CH) due to DUOX2 mutations. PATIENTS: Twenty-five patients were identified by a neonatal screening program and included seven familial cases. Their serum TSH values ranged from 18.9 to 734.6 mU/l. Twenty-two of the patients had low serum free thyroxine (fT4) levels (0.17-1.1 ng/dl). Twenty-four of the patients were treated with L-thyroxine. METHODS: We analyzed the DUOX2, thyroid peroxidase, Na(+)/I(-) symporter, and dual oxidase maturation factor 2 genes of these 25 patients by PCR-amplified direct sequencing. An additional 11 genes were analyzed in 11 of the 25 patients using next-generation sequencing. RESULTS: All patients had biallelic DUOX2 mutations, and seven novel alleles were detected. Fourteen of the patients were able to discontinue replacement therapy, and seven were receiving reduced L-thyroxine doses. Normalization of thyroglobulin lagged several years behind the completion of treatment. Two patients showed permanent hypothyroidism. Except for one case of a learning disability, growth and psychomotor development were normal. CONCLUSION: The prognosis of Japanese patients with DUOX2 defects was usually transient CH. Delayed improvement of thyroglobulin indicates that these patients have subclinical hypothyroidism. Hypothyroidism did not recur in patients during the study period (up to 18 years old).
Authors: Maricel F Molina; Patricia Papendieck; Gabriela Sobrero; Viviana A Balbi; Fiorella S Belforte; Elena Bueno Martínez; Ezequiela Adrover; María C Olcese; Ana Chiesa; Mirta B Miras; Verónica G González; Mauricio Gomes Pio; Rogelio González-Sarmiento; Héctor M Targovnik; Carina M Rivolta Journal: Endocrine Date: 2022-05-04 Impact factor: 3.925
Authors: Víctor Borda; Isabela Alvim; Marla Mendes; Carolina Silva-Carvalho; Giordano B Soares-Souza; Thiago P Leal; Vinicius Furlan; Marilia O Scliar; Roxana Zamudio; Camila Zolini; Gilderlanio S Araújo; Marcelo R Luizon; Carlos Padilla; Omar Cáceres; Kelly Levano; César Sánchez; Omar Trujillo; Pedro O Flores-Villanueva; Michael Dean; Silvia Fuselli; Moara Machado; Pedro E Romero; Francesca Tassi; Meredith Yeager; Timothy D O'Connor; Robert H Gilman; Eduardo Tarazona-Santos; Heinner Guio Journal: Proc Natl Acad Sci U S A Date: 2020-12-04 Impact factor: 12.779
Authors: Helmut Grasberger; Mohamed Noureldin; Timothy D Kao; Jeremy Adler; Joyce M Lee; Shrinivas Bishu; Mohamad El-Zaatari; John Y Kao; Akbar K Waljee Journal: Sci Rep Date: 2018-07-05 Impact factor: 4.379
Authors: Catherine Peters; Adeline K Nicholas; Erik Schoenmakers; Greta Lyons; Shirley Langham; Eva G Serra; Neil J Sebire; Marina Muzza; Laura Fugazzola; Nadia Schoenmakers Journal: Thyroid Date: 2019-06 Impact factor: 6.568